Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

Ellipse™

Implantable Cardioverter Defibrillator (ICD)

How It Works

How it Works

Greater Programming Flexibility with DeFT Response™ Technology

DeFT Response technology offers the most highly adaptable, non-invasive programming options to rapidly optimize therapy performance to each patient’s unique needs.

DeFT Response technology is only available in Abbott high-voltage devices.

With DeFT Response technology, physicians gain:

  • Non-invasive programming flexibility in the management of defibrillation thresholds (DFTs) to ensure adequate safety margins with exceptional energy delivery.
  • More options for adapting to changing patient conditions following implant with or without induction testing. These options are intended to help physicians prevent fluctuations in DFTs and a diminished safety margin.1-10
  • Pulse width programmability, available only from Abbott, which lets physicians choose the duration of each phase of the shock from 2.0 ms to 6.5 ms with or without induction testing. This method lets physicians precisely match the biphasic waveform to a patient’s unique membrane response time.11-14

The physiologic variability in the patient population means that optimal truncation times are often different between individuals. By varying waveform pulse widths, DeFT Response technology allows flexibility and patient-specific programming options.

Line graph showing the shock truncation, voltage and membrane response of the Ellipse ICD

Added Protection with SecureSense™ RV Lead Noise Discrimination Algorithm
 

The SecureSense RV lead noise discrimination algorithm offers added protection from lead noise to reduce unnecessary therapy. It can be programmed to alert a health care professional via Merlin.net™ Patient Care Network (PCN), allowing for more rapid, clinical decision making. Programmable alerts notify the patient and clinician when lead noise is detected.

Compare sensed events on primary and secondary channels. Compare rate, diagnose lead noise, inhibit or delivery therapy.

Improved Therapy Assurance with DynamicTx™ Over-Current Detection Algorithm
 

DynamicTx over-current detection algorithm is designed to provide enhanced patient safety and improved therapy assurance in the event of compromised high-voltage lead integrity, and is only available in the Abbott high-voltage portfolio.

Note

  • Alternate vector options available: RV-can and RV-SVC
  • Vector switching sequence varies based on programmed configuration

Requirements

  • Dual coil lead
  • Programmed configuration not RV-can
Flow chart showing 4 steps: HV Shock attempted, high current detected, alternate vector switch, and HV shock delivered.

Proven Reliability and Performance

More than 10 years of data from the industry's largest, prospective, actively monitored registry studies confirms the reliability of high-voltage leads with Optim™ lead insulation.

100% freedom
from externalized conductor failures15

98.9% freedom
from all-cause insulation abrasion failures15

95.9% freedom
from all-cause mechanical failures15

85% reduction in abrasion risk
with Optim leads compared to silicone insulated leads15

In addition, studies have confirmed the abrasion resistance and biostability of Optim lead insulation:

No externalized conductors in more than 8,000 Durata™ defibrillation leads implanted for more than 10 years.15

No structural defects seen in cohort of patients analyzed among > 400 patients studied in > 4-year period.16

No chemical or physical degradation seen after prolonged exposure to the in vivo environment among leads implanted up to 5 years.17

Manuals & Resources

Manuals & Resources

Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

References

  1. Shukla HH, Flaker GC, Jayam V, Roberts D. High defibrillation thresholds in transvenous biphasic implantable defibrillators: clinical predictors and prognostic implications. PACE. 2003;26(1 Pt 1):44-48.
  2. Tokano, T., Pelosi, F., Flemming, M., Horwood, L., Souza, J. J., Zivin, A., . . . Strickberger, S. A. Long-term evaluation of the ventricular defibrillation energy requirement. Journal of Cardiovascular Electrophysiology, 1998;9, 916-920.
  3. Wase, A., Basit, A., Nazir, R., Jamal, A., Shah, S., Khan, T., . . . McCullough, P. A. Impact of chronic kidney disease upon survival among implantable cardioverter defibrillator recipients. Journal of Interventional Cardiac Electrophysiology, 2004;11(3), 199-204.
  4. Stephenson, E. A., Cecchin, F., Walsh, E. P., & Berul, C. I. Utility of routine follow-up defibrillator threshold testing in congenital heart disease and pediatric populations. Journal of Cardiovascular Electrophysiology, 2005;16(1), 69-73.
  5. Nielsen, T. D., Hamdan, M. H., Kowal, R. C., Barbera, S. J., Page, R. L., Joglar, J. A. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. American Journal of Cardiology, 2001;88(4), 446-448.
  6. Pelosi, F. Jr, Oral, H., Kim, M. H., Sticherling, C., Horwood, L., Knight, B. P., . . . Strickberger, S. A. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. Journal of Cardiovascular Electrophysiology, 2000;11(7), 736-740.
  7. Crystal, E., Ovsyshcher, I. E., Wagshal, A. B., Katz, A., & Ilia, R. Mexiletine related chronic defibrillation threshold elevation: case report and review of the literature. PACE, 2002;25(4 Pt 1), 507-508.
  8. McBride, B. F., White, C. M., Kalus, J. S., Guertin, D. C., Clyne, C. A., Baker, W. L., & Kluger, J. The impact of carvedilol on the defibrillation threshold. Heart & Lung: Journal of Acute & Critical Care, 2008;37(1), 67-71.
  9. Carnes, C. A., Pickworth, K. K., Votolato, N. A., & Rarman, S. V. Elevated defibrillation threshold with venlafaxine therapy. Pharmacotherapy, 2004;24(8), 1095-1098.
  10. Shinlapawittayatorn, K., Sangnoon, R., Chattipakorn, S., Suriyasataporn, W., & Chattipakorn, N. Sildenafil citrate markedly increases defibrillation threshold in swine. Journal of the American College of Cardiology, 2005;45(3), 110A.
  11. Keane, D., Aweh, N., Hynes, B., Sheahan, R. G., Cripps, T., Bashir, Y., . . . Kroll, M. K. Achieving sufficient safety margins with fixed duration waveforms and the use of multiple time constants. PACE, 2007;30(5), 596-602.
  12. Natarajan, S., Henthorn, R., Burroughs, J., Esberg, D., Zweibel, S., Ross, T., . . . Oza, A. “Tuned” defibrillation waveforms outperform 50/50% tilt defibrillation waveforms: a randomized multicenter study. PACE, 2007;30(11), 1424.
  13. Denman, R. A., Umesan, C., Martin, P. T., Forbes, R. N., Kroll, M. W., Anskey, E. J., & Burnett, H. E. Benefit of millisecond waveform durations for patients with high defibrillation thresholds. Heart Rhythm, 2006;3(5), 536-541.
  14. Mouchawar, G., Kroll, M., Val-Mejias, J. E., Schwartzman, D., McKenzie, J., Fitzgerald, D., . . . Syed, Z. ICD waveform optimization: a randomized, prospective, pair-sampled multicenter study. PACE, 2000; 23(11 Pt 2), 1992-1995.
  15. Abbott. Product Performance Report. 2020. 1st edition. SJM-ELP-90624466 REV A.
  16. Forleo, G. B., Biase, L. D., Panattoni, G., Politano, A., Magliano, G., Santini, L., . . . Romeo, F. Systematic fluoroscopic and electrical assessment of implantable cardioverter-defibrillator patients implanted with silicone-polyurethane copolymer (Optim) coated leads. Europace, 2013;16(2), 265-270.
  17. Wilkoff, B. Characterization of the Biostability of Insulation Materials in Human Biologically Stressed Cardiac Leads [Abstract]. Presented at Heart Rhythm Society, San Francisco, CA. 2014;AB05-01.

MAT-2009580 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-1900882 v12.0